Menstrual Blood Stem Cells Show Promise in Osteoarthritis Treatment

Osteoarthritis disproportionately affects postmenopausal women, leading to joint pain in areas like the knees, hips, fingers, shoulders, and ankles.

Image credit:© iStock.com, Tingting Ji

More than 600 million people worldwide suffer from osteoarthritis—a progressive, degenerative joint disorder causing cartilage damage, loss of joint function, and chronic pain. Current treatments often focus on pain management rather than repairing damaged cartilage. In advanced cases, joint replacement surgery becomes necessary.

Women account for 60% of osteoarthritis cases, with risk increasing significantly after menopause. A surprising source of potential regenerative therapy lies in a substance postmenopausal women no longer produce—menstrual blood.

Menstrual Blood Contains Regenerative Stem Cells

Menstrual blood is rich in mesenchymal stromal cells—multipotent stem cells capable of differentiating into bone, cartilage, blood vessels, and lymphatic tissues. “These cells remain highly active as they regenerate the endometrial lining monthly, which may also stimulate regeneration in other tissues,” explains Ilona Uzieliene, a stem cell researcher at Kaunas University of Technology and coauthor of the study.

Unlike invasive sources like bone marrow, menstrual blood allows for easy, consensual sample collection, avoiding ethical concerns tied to embryonic stem cells.

[Removed promotional content]

Related Advances in Cell Biology Research

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter contentSubscribe

[Removed promotional call-to-action]

Extracellular Vesicles Drive Cartilage Regeneration

Menstrual blood stems cells secrete extracellular vesicles (EVs)—nanoscale particles containing lipids, proteins, microRNAs, and cellular proteins critical for tissue repair. “EVs act as messengers between cells, carrying signals that can trigger regeneration,” notes Divyesh Joshi, a researcher at Yale University studying cardiovascular biology.

In experiments, Uzieliene’s team cultured chondrocytes—cartilage cells—and treated them with EVs from menstrual blood stromal cells. The treated cells absorbed the vesicles and demonstrated cartilage regeneration capabilities.

Restoring Cartilage Architecture

Cartilage’s resilience relies on its extracellular matrix (ECM), a scaffold made by chondrocytes containing proteoglycans and lubricating fluid. During osteoarthritis, this matrix breaks down, and inflammatory byproducts accumulate in the fluid, accelerating cartilage destruction.

Using a 3D tissue model mimicking human cartilage, researchers found that chondrocytes exposed to menstrual blood-derived EVs synthesized more ECM and produced higher proteoglycan levels than controls. This suggests the therapy could rebuild damaged tissue.

To test efficacy in real-world scenarios, the team applied EVs to discarded cartilage explants from advanced osteoarthritis patients. Even in an inflammatory environment, the vesicles reduced ECM breakdown. “This indicates potential for treating severe cases,” says Dimitrios Kouroupis, a researcher at the University of Miami.

Treated cells also showed increased expression of cartilage-specific genes and interleukin-6 (IL-6), suggesting coordinated tissue repair mechanisms.

[Removed “Continue reading below…” prompts]

Challenges and Future Directions

Joshi highlights a key limitation: “We still don’t fully understand how EVs accomplish tissue repair. Current studies focus on single markers like IL-6 at one time point, making it hard to confirm anti-inflammatory effects.”

Toward Clinical Applications

Both researchers envision cell-free therapies using stem cell secretions like EVs as next-generation osteoarthritis treatments. Advantages include precise dosing, no risk of immune rejection, and scalability. Uzieliene remains optimistic, noting, “Storing menstrual blood samples could enable personalized medicine—using a woman’s youthful blood for later treatments.”

Source link